Recursion Pharmaceuticals Inc (RXRX)
9.51
-0.50
(-5.00%)
USD |
NASDAQ |
May 16, 16:00
9.51
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Enterprise Value: 1.965B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 1.965B |
| May 15, 2024 | 2.084B |
| May 14, 2024 | 2.093B |
| May 13, 2024 | 1.958B |
| May 10, 2024 | 1.749B |
| May 09, 2024 | 1.758B |
| May 08, 2024 | 1.746B |
| May 07, 2024 | 1.794B |
| May 06, 2024 | 1.830B |
| May 03, 2024 | 1.806B |
| May 02, 2024 | 1.794B |
| May 01, 2024 | 1.687B |
| April 30, 2024 | 1.563B |
| April 29, 2024 | 1.652B |
| April 26, 2024 | 1.633B |
| April 25, 2024 | 1.567B |
| April 24, 2024 | 1.591B |
| April 23, 2024 | 1.534B |
| April 22, 2024 | 1.510B |
| April 19, 2024 | 1.451B |
| April 18, 2024 | 1.462B |
| April 17, 2024 | 1.479B |
| April 16, 2024 | 1.503B |
| April 15, 2024 | 1.555B |
| April 12, 2024 | 1.702B |
| Date | Value |
|---|---|
| April 11, 2024 | 1.823B |
| April 10, 2024 | 1.743B |
| April 09, 2024 | 1.864B |
| April 08, 2024 | 1.842B |
| April 05, 2024 | 1.811B |
| April 04, 2024 | 1.778B |
| April 03, 2024 | 1.826B |
| April 02, 2024 | 1.788B |
| April 01, 2024 | 1.930B |
| March 31, 2024 | 2.073B |
| March 28, 2024 | 1.949B |
| March 27, 2024 | 1.996B |
| March 26, 2024 | 2.031B |
| March 25, 2024 | 2.080B |
| March 22, 2024 | 2.071B |
| March 21, 2024 | 2.109B |
| March 20, 2024 | 2.207B |
| March 19, 2024 | 2.132B |
| March 18, 2024 | 2.289B |
| March 15, 2024 | 2.242B |
| March 14, 2024 | 2.139B |
| March 13, 2024 | 2.186B |
| March 12, 2024 | 2.083B |
| March 11, 2024 | 2.043B |
| March 08, 2024 | 2.235B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
276.51M
Minimum
May 11 2022
6.341B
Maximum
Jul 13 2021
1.866B
Average
1.425B
Median
Feb 04 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 756.59B |
| Absci Corp | 381.52M |
| Palatin Technologies Inc | 23.43M |
| Oragenics Inc | 5.770M |
| Actinium Pharmaceuticals Inc | 209.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.37M |
| Revenue (Quarterly) | 13.49M |
| Total Expenses (Quarterly) | 109.83M |
| EPS Diluted (Quarterly) | -0.39 |
| Gross Profit Margin (Quarterly) | 17.23% |
| Profit Margin (Quarterly) | -677.3% |
| Earnings Yield | -17.03% |
| Normalized Earnings Yield | -17.03 |